Dimerix Ltd

DXB

Company Profile

  • Business description

    Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.

  • Contact

    425 Smith Street
    FitzroyVIC3065
    AUS

    T: +61 1300813321

    https://www.dimerix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    9

Stocks News & Analysis

stocks

Oracle shares are up 87% in 2025. Is it a buy?

Oracle’s cloud database business is riding the AI wave.
stocks

Bumper crop to benefit ASX listed share

We raise our earnings forecast 11% for next year.
stocks

Is there a long-term buying opportunity in luxury stocks?

Our analysts think the recent wobble in revenue growth is cyclical, not structural.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,137.8014.900.16%
CAC 407,872.0241.910.54%
DAX 4023,611.3384.280.36%
Dow JONES (US)46,253.34128.20-0.28%
FTSE 1009,223.323.36-0.04%
HKSE26,159.12185.02-0.70%
NASDAQ22,564.10224.88-0.99%
Nikkei 22545,493.66447.850.99%
NZX 50 Index13,136.545.00-0.04%
S&P 5006,652.2341.52-0.62%
S&P/ASX 2008,845.9014.300.16%
SSE Composite Index3,821.836.74-0.18%

Market Movers